Study Summary
This is a phase l, single arm, prospective open, dose-escalation study in patients with relapsed or refractory CD19-positive B cell malignancies (ALL, NHL, CLL). The trial will include adult and pediatric patients. There will be three individual cohorts, defined by disease biology: pediatric ALL and aggressive pediatric NHL (Cohort 1), adult ALL (Cohort 2) and adult NHL/CLL (Cohort 3).
Want to learn more about this trial?
Request More InfoInterventions
CyclophosphamideDRUG
Cyclophosphamide 60mg/Kg on day -6
FludarabineDRUG
Fludarabine 25mg/m\^2 IV on days -5 to -3
Chimeric antigen receptor T cells to be implemented in a "3 + 3" design on day 0BIOLOGICAL
Level -1 (1 x 105 cells/kg)
Level 1 \[Starting dose\] (5 x 105 cells/kg)
Level 2 (1 x 106 cells/kg)
Level 3 (2 x 106 cells/kg)
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Hospital Israelita Albert Einstein | São Paulo | São Paulo | Brazil |